Newswire (Published: Wednesday, October 4, 2017, Received: Thursday, September 28, 2017, 3:32:04 PM CDT)

Word Count: 457

New Prostate Cancer Data Have Been Reported by Researchers at Third Military Medical University (Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-beta 1/STAT3 axis-regulated EMT)

By a News Reporter-Staff News Editor at Biotech Week -- Data detailed on Oncology - Prostate Cancer have been presented. According to news originating from Chongqing, People's Republic of China, by NewsRx correspondents, research stated, "Although the newly developed second-generation anti-androgen drug enzalutamide can repress prostate cancer progression significantly, it only extends the survival of prostate cancer patients by 4-6 months mainly due to the occurrence of enzalutamide resistance. Most of the previous studies on AR antagonist resistance have been focused on AR signaling."

Our news journalists obtained a quote from the research from Third Military Medical University, "Therefore, the non-AR pathways on enzalutamide resistance remain largely unknown. By using C4-2, CWR22Rv1 and LNCaP cell lines, as well as mice bearing CWR22Rv1 xenografts treated with either enzalutamide or metformin alone or in combination, we demonstrated that metformin is capable of reversing enzalutamide resistance and restores sensitivity of CWR22Rv1 xenografts to enzalutamide. We showed that metformin alleviated resistance to enzalutamide by inhibiting EMT. Furthermore, based on the effect of metformin on the activation of STAT3 and expression of TGF-beta 1, we propose that metformin exerts its effects by targeting the TGF-beta 1/STAT3 axis."

According to the news editors, the research concluded: "These findings suggest that combination of metformin with enzalutamide could be a more efficacious therapeutic strategy for the treatment of castration-resistant prostate cancer."

For more information on this research see: Metformin reverses prostate cancer resistance to enzalutamide by targeting TGF-beta 1/STAT3 axis-regulated EMT. Cell Death & Disease, 2017;8():526-533. Cell Death & Disease can be contacted at: Nature Publishing Group, Macmillan Building, 4 Crinan St, London N1 9XW, England. (Nature Publishing Group - www.nature.com/; Cell Death & Disease - www.nature.com/cddis/)

The news correspondents report that additional information may be obtained from W.H. Lan, Third Military Medical University, Daping Hosp, Dept. of Urol, Inst Surg Res, Chongqing 400042, People's Republic of China. Additional authors for this research include D.L. Tong, G.L. Liu, J. Xu, K. Do, K. Geary, D.Z. Zhang, J. Zhang, Y. Zhang, Y.M. Li, G. Bi, Q.L. Liu and J. Jiang (see also Oncology - Prostate Cancer).

Keywords for this news article include: Chongqing, People's Republic of China, Asia, Drugs and Therapies, Hypoglycemic Agents, Antidiabetic Agents, Prostatic Neoplasms, Xenotransplantion, Metformin Therapy, Non-Sulfonylureas, Prostate Cancer, Biotechnology, Xenografts, Biguanides, Oncology, Third Military Medical University.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Places

Eastern Asia
Northern Europe
People's Republic of China
United Kingdom
Asia
Europe
England
Chongqing
London

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
      Health Sciences
            Medical Research
      Treatments and Therapies
            Growth Factors and Cytokines
Politics and Government
      National Security